CRISPR THERAPEUTICS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 55.05 USD | -1.98% |
|
-9.26% | -12.06% |
| Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
| Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 121M | Sales 2025 * | 404M | Capitalization | 4.67B |
|---|---|---|---|---|---|
| Net income 2024 * | -454M | Net income 2025 * | -381M | EV / Sales 2024 * | 25.7 x |
| Net cash position 2024 * | 1.55B | Net cash position 2025 * | 1.39B | EV / Sales 2025 * | 8.12 x |
| P/E ratio 2024 * |
-10
x | P/E ratio 2025 * |
-12.9
x | Employees | 407 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on CRISPR Therapeutics AG
More recommendations
More press releases
More news
| 1 day | -1.98% | ||
| 1 week | -9.26% | ||
| Current month | -19.23% | ||
| 1 month | -23.50% | ||
| 3 months | -11.20% | ||
| 6 months | +38.39% | ||
| Current year | -12.06% |
1 week
54.28
60.95
1 month
54.2875.91
Current year
54.2891.10
1 year
37.5591.10
3 years
37.55169.76
5 years
32.30220.20
10 years
11.63220.20
| Managers | Title | Age | Since |
|---|---|---|---|
Samarth Kulkarni
CEO | Chief Executive Officer | 45 | 15-07-31 |
Raju Prasad
DFI | Director of Finance/CFO | 40 | 23-03-13 |
Stephen Kennedy
CTO | Chief Tech/Sci/R&D Officer | 67 | 19-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Doug Treco Treco
BRD | Director/Board Member | 66 | 20-06-10 |
Simeon George
BRD | Director/Board Member | 46 | 15-04-28 |
Ali Behbahani
BRD | Director/Board Member | 47 | 15-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 10.82% | 215 M€ | +13.63% | - | |
| 8.55% | 2 M€ | -25.75% | ||
| 4.84% | 1 M€ | 0.00% | - | |
| 4.53% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 55.05 | -1.98% | 1,765,419 |
| 24-04-18 | 56.16 | +1.08% | 1,745,393 |
| 24-04-17 | 55.56 | -4.14% | 1,399,569 |
| 24-04-16 | 57.96 | -1.29% | 1,176,528 |
| 24-04-15 | 58.72 | -3.21% | 1,468,392 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Calendar
2024-04-29
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
55.05
USD
Average target price
88.12
USD
Spread / Average Target
+60.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.06% | 4.77B | |
| -1.42% | 41.35B | |
| +42.15% | 40.38B | |
| +1.97% | 39.05B | |
| -14.19% | 26.67B | |
| +1.82% | 24.07B | |
| -24.55% | 18.36B | |
| -4.07% | 11.68B | |
| +21.36% | 11.6B | |
| +8.20% | 11.15B |
- Stock Market
- Equities
- CRSP Stock
